Nine weeks versus 1 year adjuvant trastuzumab in combination with

Trastuzumab - Cancer Precision Medicine trastuzumab A study of more than 4000 patients, published in 2014, showed that adding trastuzumab to chemotherapy led to a 37% relative improvement in trastuzumab Trastuzumab works by binding to HER2, a protein involved in cell growth found in large amounts on some cancer cells This binding blocks the

trastuzumab Trastuzumab prolongs survival in metastatic breast cancer patients whose tumors over express HER2 It is effective when given as a single agent or in